Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2007

View Archived Issues

Primate studies elucidate activity of novel small-molecule, cholesterol-lowering agents

Vasohibin beneficial in early diabetic nephropathy model

A TGF-beta inhibitor protects against radiation-induced lung damage

Insmed positioned to initiate clinical studies of follow-on biologics products

Cardium initiates phase IIb MATRIX clinical study of Excellarate for diabetic ulcers

Pharmacological interventions for hepatic pathologies discussed at Liver Meeting

Merck Serono extends rights to Rigel's R-763/AS-703569 to include Japan

Advanced Life Sciences reports positive results from Trial CL-05 of cethromycin

BioLineRx enters worldwide license agreement with Yissum and Hadasit for BL-4060

Nymox completes 2-year follow-up study of NX-1207 for benign prostatic hyperplasia

Novartis initiates phase II study of QVA-149 for chronic obstructive pulmonary disease

Panacea makes CC Detect available as diagnostic test for colon cancer

Introgen reports summary data from clinical studies of p53 tumor suppressor Advexin

HealthLinx successfully completes phase II biomarker trial on the OvPlex panel

Innovive initiates STAR-1 phase II clinical trial of tamibarotene

Cogentus initiates phase III clinical trials of CGT-2168 in antiplatelet therapy

Novel antiobesity agents described in recent patent literature

Genta reports positive data from phase I clinical trial of G-4544 for accelerated bone loss

Taisho reports on novel antagonists of the MCH receptor 1

FDA authorizes IND for Athersys' MultiStem for bone marrow transplant support

LipoNova confirms U.S. and E.U. registration strategy for renal cell cancer vaccine Reniale

Adventrx meets primary endpoint in bioequivalence clinical study of ANX-530

FDA accepts Discovery Laboratories' response to approvable letter for Surfaxin

Thallion reports positive safety and efficacy data from phase I/II trial of ECO-4601

Gilead submits NDA to FDA for aztreonam lysine for inhalation for cystic fibrosis

CHMP adopts negative opinion on marketing authorization for Tysabri for Crohn's disease

FDA approves supplemental NDA for Nexavar for unresectable hepatocellular carcinoma

CHMP recommends extended indication for Angiox for acute coronary syndromes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...